Literature DB >> 19193248

Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives.

Stephen G Grant1, Melissa A Melan, Jean J Latimer, Paula A Witt-Enderby.   

Abstract

Recent studies have suggested that the pineal hormone melatonin may protect against breast cancer, and the mechanisms underlying its actions are becoming clearer. Melatonin works through receptors and distinct second messenger pathways to reduce cellular proliferation and to induce cellular differentiation. In addition, independently of receptors melatonin can modulate oestrogen-dependent pathways and reduce free-radical formation, thus preventing mutation and cellular toxicity. The fact that melatonin works through a myriad of signalling cascades that are protective to cells makes this hormone a good candidate for use in the clinic for the prevention and/or treatment of cancer. This review summarises cellular mechanisms governing the action of melatonin and then considers the potential use of melatonin in breast cancer prevention and treatment, with an emphasis on improving clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193248      PMCID: PMC4301735          DOI: 10.1017/S1462399409000982

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  112 in total

1.  The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia.

Authors:  P Lissoni; G Tancini; S Barni; F Paolorossi; F Rossini; P Maffé; L Di Bella
Journal:  Recenti Prog Med       Date:  1996-12

Review 2.  Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy.

Authors:  Paula A Witt-Enderby; Nicholas M Radio; John S Doctor; Vicki L Davis
Journal:  J Pineal Res       Date:  2006-11       Impact factor: 13.007

3.  Daily rhythms of melatonin binding sites in the rat pars tuberalis and suprachiasmatic nuclei; evidence for a regulation of melatonin receptors by melatonin itself.

Authors:  F Gauer; M Masson-Pévet; D J Skene; B Vivien-Roels; P Pévet
Journal:  Neuroendocrinology       Date:  1993-01       Impact factor: 4.914

4.  Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro.

Authors:  Mercedes M Leon-Blanco; Juan M Guerrero; Russel J Reiter; Juan R Calvo; David Pozo
Journal:  J Pineal Res       Date:  2003-10       Impact factor: 13.007

Review 5.  Estrogens and epithelial ovarian cancer.

Authors:  Séverine Cunat; Pascale Hoffmann; Pascal Pujol
Journal:  Gynecol Oncol       Date:  2004-07       Impact factor: 5.482

6.  Modulation of intracellular calcium and calmodulin by melatonin in MCF-7 human breast cancer cells.

Authors:  Jun Dai; Edward W Inscho; Lin Yuan; Steven M Hill
Journal:  J Pineal Res       Date:  2002-03       Impact factor: 13.007

7.  Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin.

Authors:  Beatriz del Río; Juana M García Pedrero; Carlos Martínez-Campa; Pedro Zuazua; Pedro S Lazo; Sofía Ramos
Journal:  J Biol Chem       Date:  2004-06-30       Impact factor: 5.157

Review 8.  Light at night, chronodisruption, melatonin suppression, and cancer risk: a review.

Authors:  Russel J Reiter; Dun-Xian Tan; Ahmet Korkmaz; Thomas C Erren; Claus Piekarski; Hiroshi Tamura; Lucien C Manchester
Journal:  Crit Rev Oncog       Date:  2007-12

9.  Correlative association between circadian expression of mousePer2 gene and the proliferation of the neural stem cells.

Authors:  T Moriya; K Hiraishi; N Horie; M Mitome; K Shinohara
Journal:  Neuroscience       Date:  2007-03-26       Impact factor: 3.590

Review 10.  Cancer biomarkers: knowing the present and predicting the future.

Authors:  Sabarni K Chatterjee; Bruce R Zetter
Journal:  Future Oncol       Date:  2005-02       Impact factor: 3.404

View more
  38 in total

Review 1.  Melatonin: an inhibitor of breast cancer.

Authors:  Steven M Hill; Victoria P Belancio; Robert T Dauchy; Shulin Xiang; Samantha Brimer; Lulu Mao; Adam Hauch; Peter W Lundberg; Whitney Summers; Lin Yuan; Tripp Frasch; David E Blask
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

2.  Melatonin represses oral squamous cell carcinoma metastasis by inhibiting tumor-associated neutrophils.

Authors:  Haibin Lu; Baolei Wu; Ge Ma; Deyu Zheng; Ruijuan Song; Erjiang Huang; Ming Mao; Bin Lu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

3.  Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs.

Authors:  Mahmud Hasan; Mohamed Akmal Marzouk; Saugat Adhikari; Thomas D Wright; Benton P Miller; Margarite D Matossian; Steven Elliott; Maryl Wright; Madlin Alzoubi; Bridgette M Collins-Burow; Matthew E Burow; Ulrike Holzgrabe; Darius P Zlotos; Robert E Stratford; Paula A Witt-Enderby
Journal:  Mol Pharmacol       Date:  2019-06-20       Impact factor: 4.436

4.  Mechanisms regulating angiogenesis underlie seasonal control of pituitary function.

Authors:  Jennifer Castle-Miller; David O Bates; Domingo J Tortonese
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-07       Impact factor: 11.205

5.  Fluorine substituted methoxyphenylalkyl amides as potent melatonin receptor agonists.

Authors:  Andrew Tsotinis; Rodanthi Kompogennitaki; Ioannis Papanastasiou; Peter J Garratt; Alina Bocianowska; David Sugden
Journal:  Medchemcomm       Date:  2019-02-11       Impact factor: 3.597

6.  Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort.

Authors:  Theodore M Brasky; Johanna W Lampe; John D Potter; Ruth E Patterson; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07       Impact factor: 4.254

7.  A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes.

Authors:  Wendy Y Chen; Anita Giobbie-Hurder; Kathryn Gantman; Jennifer Savoie; Rochelle Scheib; Leroy M Parker; Eva S Schernhammer
Journal:  Breast Cancer Res Treat       Date:  2014-04-10       Impact factor: 4.872

Review 8.  Does current scientific evidence support a link between light at night and breast cancer among female night-shift nurses? Review of evidence and implications for occupational and environmental health nurses.

Authors:  Barbra Dickerman; Jianghong Liu
Journal:  Workplace Health Saf       Date:  2012-06       Impact factor: 1.413

9.  Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature.

Authors:  Michelle Basler; Alexander Jetter; Daniel Fink; Burkhardt Seifert; Gerd A Kullak-Ublick; Andreas Trojan
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

10.  CCAR2 deficiency augments genotoxic stress-induced apoptosis in the presence of melatonin in non-small cell lung cancer cells.

Authors:  Wootae Kim; Joo-Won Jeong; Ja-Eun Kim
Journal:  Tumour Biol       Date:  2014-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.